Show simple item record

AuthorCenciarelli, Carlo
AuthorE. Marei, Hany
AuthorZonfrillo, Manuela
AuthorCasalbore, Patrizia
AuthorFelsani, Armando
AuthorTrevisi, Gianluca
AuthorAlthani, Asma
AuthorMangiola, Annunziato
Available date2017-02-13T08:40:59Z
Publication Date2017-02-02
Publication NameOncotargeten_US
URIhttp://hdl.handle.net/10576/5244
AbstractThe invasive and lethal nature of Glioblastoma multiforme (GBM) necessitates the continuous identification of molecular targets and search of efficacious therapies to inhibit GBM growth. The GBM resistance to chemotherapy and radiation it is attributed to the existence of a rare fraction of cancer stem cells (CSC) that we have identified within the tumor core and in peritumor tissue of GBM. Since Notch1 pathway is a potential therapeutic target in brain cancer, earlier we highlighted that pharmacological inhibition of Notch1 signalling by γ-secretase inhibitor-X (GSI-X), reduced cell growth of some c-CSC than to their respective p-CSC, but produced negligible effects on cell cycle distribution, apoptosis and cell invasion. In the current study, we assessed the effects of Hes1-targeted shRNA, a Notch1 gene target, specifically on GBM CSC refractory to GSI-X. Depletion of Hes1 protein induces major changes in cell morphology, cell growth rate and in the invasive ability of shHes1-CSC in response to growth factor EGF. shHes1-CSC show a decrease of the stemness marker Nestin concurrently to a marked increase of neuronal marker MAP2 compared to pLKO.1-CSC. Those effects correlated with repression of EGFR protein and modulation of Stat3 phosphorylation at Y705 and S727 residues. In the last decade Stat3 has gained attention as therapeutic target in cancer but there is not yet any approved Stat3-based glioma therapy. Herein, we report that exposure to a Stat3/5 inhibitor, induced apoptosis either in shHes1-CSC or control cells. Taken together, Hes1 seems to be a favorable target but not sufficient itself to target GBM efficaciously, therefore a possible pharmacological intervention should provide for the use of anti-Stat3/5 drugs either alone or in combination regimen.
Languageen
PublisherImpact Journals
Subjectglioblastoma stem cells
SubjectNotch1
SubjectHes1
Subjectself-renewal
Subjectdifferentiation
TitleThe Interference of Notch1 target Hes1 affects cell growth, differentiation and invasiveness of glioblastoma stem cells through modulation of multiple oncogenic targets
TypeArticle
ESSN1949-2553


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record